Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.30 |
| ▸ | CHRNG | P07510 | 1/20 | 0.30 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.30 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
| ▸ | CHRND | Q07001 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3769871 | 0.85 | BACE1 (0.37) | — | |
| SCHEMBL3357636 | 0.85 | BACE1 (0.36) | — | |
| SCHEMBL3359617 | 0.83 | CHRNA1 (0.32) | NPSR1CHRNA1CHRNGCHRNB1CHRNB2 | |
| SCHEMBL3243724 | 0.83 | KDM1A (0.40) | CHRNA1CHRNGCHRNB1CHRNB2SLC6A2 | |
| SCHEMBL3636245 | 0.82 | BACE1 (0.47) | — | |
| SCHEMBL3773671 | 0.81 | CHRNA1 (0.32) | CHRNA1CHRNGCHRNB1CHRNB2SLC6A2 | |
| SCHEMBL3359103 | 0.81 | — | — | |
| SCHEMBL3357425 | 0.81 | — | — | |
| SCHEMBL3633790 | 0.80 | BACE1 (0.47) | — | |
| SCHEMBL3361552 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100324072-A1 | PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS BACE INHIBITORS | ASTRAZENECA AB (SE) | 2010-12-23 | — | — | US | disclosed |
| US-7629356-B2 | Substituted pyrrolo[3,4-b]pyridinamines and pharmaceutical compositions | ASTRAZENECA AB (SE) | 2009-12-08 | — | — | US | disclosed |
| US-20090233945-A9 | NEW COMPOUNDS 834 | ASTRAZENECA AB (SE) | 2009-09-17 | — | — | US | disclosed |
| US-20080287462-A1 | NEW COMPOUNDS 834 | ASTRAZENECA AB (SE) | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324072-A1 | PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS BACE INHIBITORS | BACE1, BACE2, PSEN1 | NPSR1 1577/4885CHRNA1 1583/4885CHRNG 3309/4885 |
| US-20090233945-A9 | NEW COMPOUNDS 834 | MAPT, PSEN1, PSEN2 | NPSR1 594/4885CHRNA1 120/4885CHRNG 330/4885 |
| US-20080287462-A1 | NEW COMPOUNDS 834 | MAPT, PSEN1, PSEN2 | NPSR1 594/4885CHRNA1 120/4885CHRNG 330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.